Does Rallies show Form 4 insider transactions for LNTH?

Yes. Rallies tracks LNTH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LNTH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LNTH. It does not provide personalized investment advice.

LNTH (Lantheus Holdings, Inc) Stock Analysis - Insider Trades

Lantheus Holdings, Inc (LNTH) is a publicly traded Healthcare sector company. As of May 21, 2026, LNTH trades at $95.47 with a market cap of $6.06B and a P/E ratio of 22.77. LNTH moved +3.52% today. Year to date, LNTH is +39.30%; over the trailing twelve months it is +25.07%. Its 52-week range spans $47.25 to $118.21. Analyst consensus is strong buy with an average price target of $103.25. Rallies surfaces LNTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LNTH stock inside the company?

Recent LNTH insider activity includes PATEL RAJIV A sold 3.37M, FARALLON PARTNERS L L C/CA sold 3.37M, PATEL RAJIV A sold 41.00K, FARALLON PARTNERS L L C/CA sold 41.00K, and Blanchfield Paul sold 3.06K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LNTH Key Metrics

Key financial metrics for LNTH
Metric	Value
Price	$95.47
Market Cap	$6.06B
P/E Ratio	22.77
EPS	$4.22
Dividend Yield	0.00%
52-Week High	$118.21
52-Week Low	$47.25
Volume	607.36K
Avg Volume	0
Revenue (TTM)	$1.55B
Net Income	$279.03M
Gross Margin	60.48%

Recent LNTH Insider Trades

PATEL RAJIV A sold 3.37M (~$188.94M) on Aug 20, 2025.
FARALLON PARTNERS L L C/CA sold 3.37M (~$188.94M) on Aug 20, 2025.
PATEL RAJIV A sold 41.00K (~$2.27M) on Aug 19, 2025.
FARALLON PARTNERS L L C/CA sold 41.00K (~$2.27M) on Aug 19, 2025.
Blanchfield Paul sold 3.06K (~$163.92K) on Aug 13, 2025.

Latest LNTH News

Lantheus jumps after Q1 2026 results and reaffirmed 2026 guidance — May 7, 2026
LNTH jumps ahead of May 7 earnings as PYLARIFY TruVu approval boosts optimism — Apr 30, 2026
Lantheus drops as FDA extends LNTH-2501 (OCTEVY) review to June 29, 2026 — Apr 29, 2026
FDA Extends Lantheus’s Ga 68 Edotreotide Review to June 29, 2026 — Mar 17, 2026
Lantheus Holdings Completes SPECT Divestiture as Cowen Cuts Price Target by $5 — Feb 18, 2026

LNTH Analyst Consensus

9 analysts cover LNTH: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $103.25.

Common questions about LNTH

Who is trading LNTH stock inside the company?: Recent LNTH insider activity includes PATEL RAJIV A sold 3.37M, FARALLON PARTNERS L L C/CA sold 3.37M, PATEL RAJIV A sold 41.00K, FARALLON PARTNERS L L C/CA sold 41.00K, and Blanchfield Paul sold 3.06K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LNTH?: Yes. Rallies tracks LNTH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LNTH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LNTH. It does not provide personalized investment advice.